Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 1/2 1

Status

Completed 22Recruiting 21Unknown 16Active not recruiting 16Terminated 11Withdrawn 8Not yet recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 1

Conditions

Metastatic Breast Cancer in Germline-PALB2 Mutations Carriers 1Efficacy 1

Interventions

Carboplatin 79Cisplatin 74Bevacizumab 62Radiotherapy 59Drug Therapy 57Capecitabine 57Oxaliplatin 56tislelizumab 54toripalimab 45Paclitaxel 44Gemcitabine 43pembrolizumab 40anlotinib 40Specimen Handling 39sintilimab 37Cyclophosphamide 34130-nm albumin-bound paclitaxel 34Injections 30Pemetrexed 28camrelizumab 26Surgical Procedures, Operative 26Magnetic Resonance Spectroscopy 25lenvatinib 24apatinib 23Docetaxel 23Etoposide 22S 1 (combination) 21Fluorouracil 21Immune Checkpoint Inhibitors 20Biopsy 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Not yet recruiting × niraparib × Clear all
NCT06237205 2024-02-01

Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency

Korea University Anam Hospital

Phase 2 Not yet recruiting
33 enrolled

Efficacy

NCT05232006 2022-03-08

PALB2-PARPi-01

Assistance Publique - Hôpitaux de Paris

Phase 2 Not yet recruiting
12 enrolled
Breast

Metastatic Breast Cancer in Germline-PALB2 Mutations Carriers

Data powered by HemOnc (CC BY 4.0) Colophon ⚡